Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime
Launched by LUND UNIVERSITY HOSPITAL · May 30, 2018
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Signed written informed consent.
- • Fulfils the indication of the treatment with 3-6 months oxaliplatin combined adjuvant chemotherapy.
- • Polyneuropathy grade according to CTCAE before treatment start ≤ 2.
- • Performance status according to WHO ≤ 1.
- Exclusion Criteria:
- • Age \< 18 years.
- • The patient does not consent to the examination
- • Polyneuropathy grade according to CTCAE before treatment start \>2.
- • Performance status according to WHO \>1.
About Lund University Hospital
Lund University Hospital, affiliated with Lund University in Sweden, is a leading institution in medical research and clinical trials. Renowned for its commitment to advancing healthcare through innovative research, the hospital integrates clinical practice with academic excellence. As a sponsor of clinical trials, Lund University Hospital focuses on a wide range of therapeutic areas, striving to improve patient outcomes by rigorously evaluating new treatments and interventions. With a multidisciplinary team of expert researchers and clinicians, the hospital emphasizes ethical standards, patient safety, and scientific integrity in all its studies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials